# Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT03274011** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 40 (actual)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03274011
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-06-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274011, "Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03274011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*